{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:51:44Z","timestamp":1785577904039,"version":"3.56.0"},"reference-count":42,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.3724\/abbs.2023280","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T07:31:57Z","timestamp":1702539117000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Targeted disruption of the <italic>BCR-ABL<\/italic>                     fusion gene by Cas9\/dual-sgRNA inhibits proliferation and induces apoptosis in                     chronic myeloid leukemia cells"],"prefix":"10.3724","author":[{"given":"Jianling","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","volume":"33","author":"Baccarani M","year":"2019","unstructured":"Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and                         persistence and the relationship with the BCR-ABL1 transcript type. Leukemia, 2019, 33: 2358-2364.","journal-title":"Leukemia"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11684-012-0202-x","volume":"6","author":"He H","year":"2012","unstructured":"He H, Shen Y, Zhu Y, Chen S. Prognostic analysis of chronic myeloid leukemia in Chinese                         population in an imatinib era. Front Med, 2012, 6: 204-211.","journal-title":"Front Med"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/phar.1893","volume":"37","author":"Kreys ED","year":"2017","unstructured":"Kreys ED, Frei CR, Villarreal SM, Bollinger MJ, Jones X, Koeller JM. Evaluation of long-term chronic myeloid leukemia treatment                         practices with tyrosine kinase inhibitors in a national cohort of veterans. Pharmacotherapy, 2017, 37: 278-286.","journal-title":"Pharmacotherapy"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1056\/NEJMe030009","volume":"348","author":"Peggs K","year":"2003","unstructured":"Peggs K, Mackinnon S. Imatinib mesylate\u2014\u2014the new gold standard for treatment of chronic                         myeloid leukemia. N Engl J Med, 2003, 348: 1048-1050.","journal-title":"N Engl J Med"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","volume":"16","author":"Stagno F","year":"2016","unstructured":"Stagno F, Stella S, Spitaleri A, Pennisi MS, Di Raimondo F, Vigneri P. Imatinib mesylate in chronic myeloid leukemia: frontline                         treatment and long-term outcomes. Expert Rev                             Anticancer Ther, 2016, 16: 273-278.","journal-title":"Expert Rev                             Anticancer Ther"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.leu.2404893","volume":"22","author":"Bocchia M","year":"2008","unstructured":"Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M, Pirrotta MT. CD34+\/Ph+ cells are still detectable in chronic myeloid leukemia                         patients with sustained and prolonged complete cytogenetic remission during                         treatment with imatinib mesylate. Leukemia, 2008, 22: 426-428.","journal-title":"Leukemia"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1634\/theoncologist.2009-0165","volume":"14","author":"Michael M","year":"2009","unstructured":"Michael M, Antoniades M, Lemesiou E, Papaminas N, Melanthiou F. Development of multiple myeloma in a patient with chronic myeloid                         leukemia while on treatment with imatinib mesylate for 65 months. Oncologist, 2009, 14: 1198-1200.","journal-title":"Oncologist"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1242\/dev.140855","volume":"4","author":"Bressan RB","year":"2017","unstructured":"Bressan RB, Dewari PS, Kalantzaki M, Gangoso E, Matjusaitis M, Garcia-Diaz C, Blin C. Efficient CRISPR\/Cas9-assisted gene targeting enables rapid and                         precise genetic manipulation of mammalian neural stem cells. Development, 2017, 4: 635-648.","journal-title":"Development"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"eaah3480","DOI":"10.1126\/scitranslmed.aah3480","volume":"9","author":"De Ravin SS","year":"2017","unstructured":"De Ravin SS, Li L, Wu X, Choi U, Allen C, Koontz S, Lee J. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients                         with X-linked chronic granulomatous disease. Sci Transl                             Med, 2017, 9:","journal-title":"Sci Transl                             Med"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"Eyquem J","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, Odak A. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances                         tumour rejection. Nature, 2017, 543: 113-117.","journal-title":"Nature"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"20881","DOI":"10.18632\/oncotarget.14930","volume":"8","author":"Yoshino H","year":"2017","unstructured":"Yoshino H, Yonemori M, Miyamoto K, Tatarano S, Kofuji S, Nohata N, Nakagawa M. microRNA-210-3p depletion by CRISPR\/Cas9 promoted tumorigenesis                         through revival of TWIST1 in renal cell carcinoma. Oncotarget, 2017, 8: 20881-20894.","journal-title":"Oncotarget"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"114087","DOI":"10.1016\/j.addr.2021.114087","volume":"181","author":"Bloomer H","year":"2022","unstructured":"Bloomer H, Khirallah J, Li Y, Xu Q. CRISPR\/Cas9 ribonucleoprotein-mediated genome and epigenome                         editing in mammalian cells. Adv Drug                             Deliver Rev, 2022, 181:","journal-title":"Adv Drug                             Deliver Rev"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"12267","DOI":"10.1002\/jcp.27972","volume":"234","author":"Karimian A","year":"2019","unstructured":"Karimian A, Azizian K, Parsian H, Rafieian S, Shafiei-Irannejad V, Kheyrollah M, Yousefi M. CRISPR\/Cas9 technology as a potent molecular tool for gene                         therapy. J Cell Physiol, 2019, 234: 12267-12277.","journal-title":"J Cell Physiol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"Wang SW","year":"2022","unstructured":"Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, Cai JB. Current applications and future perspective of CRISPR\/Cas9 gene                         editing in cancer. Mol Cancer, 2022, 21:","journal-title":"Mol Cancer"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neuint.2017.07.007","volume":"112","author":"Kolli N","year":"2018","unstructured":"Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL. Application of the gene editing tool, CRISPR-Cas9, for treating                         neurodegenerative diseases. Neurochem Int, 2018, 112: 187-196.","journal-title":"Neurochem Int"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/bjh.15851","volume":"185","author":"Jensen TI","year":"2019","unstructured":"Jensen TI, Axelgaard E, Bak RO. Therapeutic gene editing in haematological disorders withCRISPR                         \/Cas9. Br J Haematol, 2019, 185: 821-835.","journal-title":"Br J Haematol"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"175173","DOI":"10.1016\/j.ejphar.2022.175173","volume":"931","author":"Jena R","year":"2022","unstructured":"Jena R, Vishwas S, Kumar R, Kaur J, Khursheed R, Gulati M, Singh TG. Treatment strategies for HIV infection with emphasis on role of                         CRISPR\/Cas9 gene: success so far and road ahead. Eur J                             Pharmacol, 2022, 931:","journal-title":"Eur J                             Pharmacol"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","volume":"14","author":"Rahman M","year":"2022","unstructured":"Rahman M, Bilal M, Shah JA, Kaushik A, Teissedre PL, Kujawska M. CRISPR-Cas9-based technology and its relevance to gene editing in                         parkinson\u2019s disease. Pharmaceutics, 2022, 14:","journal-title":"Pharmaceutics"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms21249604","volume":"21","author":"Janik E","year":"2020","unstructured":"Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M. Various aspects of a gene editing system-CRISPR-Cas9. Int J Mol Sci, 2020, 21:","journal-title":"Int J Mol Sci"},{"key":"CITATION20","doi-asserted-by":"crossref","unstructured":"Leonova EI, Gainetdinov RR. CRISPR\/Cas9 technology in                         translational biomedicine.                              Cell Physiol Biochem                                                  2020, 54: 354-370.","DOI":"10.33594\/000000224"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"26027","DOI":"10.18632\/oncotarget.15215","volume":"8","author":"Garc\u00eda-Tu\u00f1\u00f3n I","year":"2017","unstructured":"Garc\u00eda-Tu\u00f1\u00f3n I, Hern\u00e1ndez-S\u00e1nchez M, Ordo\u00f1ez JL, Alonso-P\u00e9rez V, \u00c1lamo-Quijada M, Benito R, Guerrero C. The CRISPR\/Cas9 system efficiently reverts the tumorigenic                         ability of BCR\/ABL in vitro and in a xenograft model of                         chronic myeloid leukemia. Oncotarget, 2017, 8: 26027-26040.","journal-title":"Oncotarget"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/crispr.2021.0009","volume":"4","author":"Vuelta E","year":"2021","unstructured":"Vuelta E, Ordo\u00f1ez JL, Alonso-P\u00e9rez V, M\u00e9ndez L, Hern\u00e1ndez-Carabias P, Salda\u00f1a R, Sevilla J. CRISPR-Cas9 technology as a tool to target gene drivers in                         cancer: proof of concept and new opportunities to treat chronic myeloid                         leukemia. CRISPR J, 2021, 4: 519-535.","journal-title":"CRISPR J"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-019-1229-5","volume":"38","author":"Luo Z","year":"2019","unstructured":"Luo Z, Gao M, Huang N, Wang X, Yang Z, Yang H, Huang Z. Efficient disruption of BCR-ABL gene by CRISPR                         RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid                         leukemia cells. J Exp Clin                             Cancer Res, 2019, 38:","journal-title":"J Exp Clin                             Cancer Res"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.3390\/ijms23126386","volume":"23","author":"Vuelta E","year":"2022","unstructured":"Vuelta E, Ordo\u00f1ez JL, Sanz DJ, Ballesteros S, Hern\u00e1ndez-Rivas JM, M\u00e9ndez-S\u00e1nchez L, S\u00e1nchez-Mart\u00edn M. CRISPR\/Cas9-directed gene trap constitutes a selection system for                         corrected BCR\/ABL leukemic cells in cML. Int J Mol Sci, 2022, 23:","journal-title":"Int J Mol Sci"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"Braun TP","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell, 2020, 37: 530-542.","journal-title":"Cancer Cell"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","volume":"11","author":"Martinez-Lage M","year":"2020","unstructured":"Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin MC, Moya FJ, Quintana-Bustamante O. In vivo CRISPR\/Cas9 targeting of fusion                         oncogenes for selective elimination of cancer cells. Nat Commun, 2020, 11:","journal-title":"Nat Commun"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"W171","DOI":"10.1093\/nar\/gkz365","volume":"47","author":"Labun K","year":"2019","unstructured":"Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome                         editing. Nucleic Acids Res, 2019, 47: W171-W174.","journal-title":"Nucleic Acids Res"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13578-018-0200-z","volume":"8","author":"Hu Z","year":"2018","unstructured":"Hu Z, Shi Z, Guo X, Jiang B, Wang G, Luo D, Chen Y. Ligase IV inhibitor SCR7 enhances gene editing directed by                         CRISPR-Cas9 and ssODN in human cancer cells. Cell Biosci, 2018, 8:","journal-title":"Cell Biosci"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13578-019-0350-7","volume":"9","author":"Hu Z","year":"2019","unstructured":"Hu Z, Wang L, Shi Z, Jiang J, Li X, Chen Y, Li K. Customized one-step preparation of sgRNA transcription templates                         via overlapping PCR using short primers and its application in vitro                         and in vivo gene editing. Cell Biosci, 2019, 9:","journal-title":"Cell Biosci"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/OTT.S225556","volume":"Volume 13","author":"Li Y","year":"2020","unstructured":"Li Y, Li X, Qu J, Luo D, Hu Z. Cas9 mediated correction of \u03b2-catenin mutation and restoring the                         expression of protein phosphorylation in colon cancer HCT-116 cells decrease                         cell proliferation in vitro and hamper tumor growth in mice in                         vivo. Onco Targets Ther, 2020, Volume 13: 17-29.","journal-title":"Onco Targets Ther"},{"key":"CITATION31","doi-asserted-by":"crossref","unstructured":"Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y, Feng TT, et al.                         Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic                         Myeloid Leukemia.                              PLoS One                         . 2009, 4: e6257.","DOI":"10.1371\/journal.pone.0006257"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13073-015-0178-7","volume":"7","author":"Mou H","year":"2015","unstructured":"Mou H, Kennedy Z, Anderson DG, Yin H, Xue W. Precision cancer mouse models through genome editing with                         CRISPR-Cas9. Genome Med, 2015, 7:","journal-title":"Genome Med"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"Bae S","year":"2014","unstructured":"Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for                         potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics, 2014, 30: 1473-1475.","journal-title":"Bioinformatics"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.3390\/ijms20225706","volume":"20","author":"Lentsch E","year":"2019","unstructured":"Lentsch E, Li L, Pfeffer S, Ekici AB, Taher L, Pilarsky C, Gr\u00fctzmann R. CRISPR\/Cas9-mediated knock-out of KrasG12D mutated pancreatic                         cancer cell lines. Int J Mol Sci, 2019, 20:","journal-title":"Int J Mol Sci"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/cancers12061399","volume":"12","author":"Chen SH","year":"2020","unstructured":"Chen SH, Hsieh YY, Tzeng HE, Lin CY, Hsu KW, Chiang YS, Lin SM. ABL genomic editing sufficiently abolishes oncogenesis of human                         chronic myeloid leukemia cells in vitro and in vivo. Cancers, 2020, 12:","journal-title":"Cancers"},{"key":"CITATION36","doi-asserted-by":"crossref","unstructured":"Zhang L, Jia R, Palange NJ, Satheka AC, Togo J, An Y, Humphrey M,                         et al. Large genomic fragment deletions and insertions in mouse using                         CRISPR\/Cas9.                              PloS One                          2015, 10:                         e0120396.","DOI":"10.1371\/journal.pone.0120396"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00018-016-2143-z","volume":"73","author":"Song Y","year":"2016","unstructured":"Song Y, Yuan L, Wang Y, Chen M, Deng J, Lv Q, Sui T. Efficient dual sgRNA-directed large gene deletion in rabbit with                         CRISPR\/Cas9 system. Cell Mol Life                             Sci, 2016, 73: 2959-2968.","journal-title":"Cell Mol Life                             Sci"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12934-023-02214-y","volume":"22","author":"Liu C","year":"2023","unstructured":"Liu C, Yue Y, Xue Y, Zhou C, Ma Y. CRISPR-Cas9 assisted non-homologous end joining genome editing                         system of Halomonas bluephagenesis for large DNA fragment                         deletion. Microb Cell                             Fact, 2023, 22:","journal-title":"Microb Cell                             Fact"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"Doench JG","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I. Optimized sgRNA design to maximize activity and minimize                         off-target effects of CRISPR-Cas9. Nat Biotechnol, 2016, 34: 184-191.","journal-title":"Nat Biotechnol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"e1372","DOI":"10.1002\/cti2.1372","volume":"11","author":"Kaeuferle T","year":"2022","unstructured":"Kaeuferle T, Stief TA, Canzar S, Kutlu NN, Willier S, Stenger D, Ferrada\u2010Ernst P. Genome-wide off-target analyses of CRISPR\/Cas9\u2010mediated T-cell                         receptor engineering in primary human T cells. Clin Trans Imm, 2022, 11:","journal-title":"Clin Trans Imm"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"Bulcha JT","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal                             Transduct Target Ther, 2021, 6:","journal-title":"Signal                             Transduct Target Ther"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"113891","DOI":"10.1016\/j.addr.2021.113891","volume":"176","author":"Xu X","year":"2021","unstructured":"Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment. Adv Drug                             Deliver Rev, 2021, 176:","journal-title":"Adv Drug                             Deliver Rev"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/33D1A163309640BE90E40F5EBFA40A54","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2023280","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/33D1A163309640BE90E40F5EBFA40A54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T06:17:59Z","timestamp":1709101079000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2023280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":42,"URL":"https:\/\/doi.org\/10.3724\/abbs.2023280","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}